C12N 9/2474
Hyaluronoglucosaminidase , i.e. hyaluronidase
Official title: {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
C12N9/2474 (Hyaluronoglucosaminidase , i.e. hyaluronidase) appears on 97 US grants and 182 published applications in this corpus.
Search patents in C12N- Granted patents
- 97
- Published applications
- 182
- Assignees
- 68
- Inventors
- 275
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 2 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 4 |
| 2010 | 2 | 3 |
| 2011 | 0 | 2 |
| 2012 | 2 | 6 |
| 2013 | 4 | 10 |
| 2014 | 5 | 4 |
| 2015 | 3 | 6 |
| 2016 | 4 | 4 |
| 2017 | 8 | 9 |
| 2018 | 3 | 4 |
| 2019 | 5 | 8 |
| 2020 | 2 | 7 |
| 2021 | 4 | 10 |
| 2022 | 6 | 13 |
| 2023 | 3 | 18 |
| 2024 | 19 | 18 |
| 2025 | 10 | 32 |
| 2026 | 11 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Digital microbiology15 Sep 2026US 12,735,735 B2Bio-Rad Europe GmbH
- Hyaluronic acid-producing recombinant cells14 Jul 2026US 12,680,121 B2Givaudan SA
- Modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses23 Jun 2026US 12,662,664 B2Pharmact Holding AG
- Hyaluronidase enzyme formulations for high volume administration26 May 2026US 12,636,350 B2Halozyme, Inc.
- Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same5 May 2026US 12,618,055 B2Alteogen, Inc.
- Egfr and c-met binding agent variants and methods of use1 Oct 2026US 2026/0297201 A1Janssen Biotech, Inc.
- Pharmaceutical composition for subcutaneous administration containing human hyaluronidase ph20 variant and drug1 Oct 2026US 2026/0297215 A1Alteogen, Inc.
- Ph20 polypeptide variants, formulations and uses thereof1 Oct 2026US 2026/0297551 A1Halozyme, Inc.
- Ph20 polypeptide variants, formulations and uses thereof17 Sep 2026US 2026/0275318 A1Halozyme, Inc.
- Hyaluronidase Enzyme Formulations for High Volume Administration27 Aug 2026US 2026/0248895 A1Halozyme, Inc.
Most cited
By later US patents
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof135US 7,767,429 B2Halozyme, Inc. · 2010
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof81US 8,431,380 B2Halozyme, Inc. · 2013
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof75US 8,202,517 B2Halozyme, Inc. · 2012
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof73US 8,450,470 B2Halozyme, Inc. · 2013
- Use of human plasma hyaluronidase in cancer treatment72US 7,148,201 B2The Regents of the University of California · 2006